Payment overview · 2025
General Payments
$335.30
4 reported records · 2 companies
Healthcare provider profile · identity verified
Samer Al-Ameri, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BANGOR, ME · NPI 1225514854
Verified facts
What the public records show
CMS Open Payments records show Samer Al-Ameri, MD received $335.30 in general payments during 2025 across 4 reported records.
AstraZeneca Pharmaceuticals LP accounted for 71.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Bevespi Aerosphere by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $240.58 | 71.8% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $94.72 | 28.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $335.30 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $126.50 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $94.72 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $87.68 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $26.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 596 | 166 |
| Lisinopril | Lisinopril | 285 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 280 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 207 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 193 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 168 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 160 | 40 |
| Omeprazole | Omeprazole | 150 | 43 |
| Losartan Potassium | Losartan Potassium | 149 | 49 |
| Gabapentin | Gabapentin | 114 | 32 |
| Furosemide | Furosemide | 110 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 30 |
| Metformin Hcl Er | Metformin Hcl | 105 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 26 |
| Mounjaro | Tirzepatide | 85 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 48 |
| Carvedilol | Carvedilol | 80 | 24 |
| Trazodone Hcl | Trazodone Hcl | 79 | 18 |
| Pregabalin | Pregabalin | 78 | 22 |
| Sertraline Hcl | Sertraline Hcl | 77 | 18 |
| Glipizide Er | Glipizide | 76 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 22 |
| Famotidine | Famotidine | 67 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 12 |
| Metformin Hcl | Metformin Hcl | 55 | 21 |
| Eliquis | Apixaban | 50 | 18 |
| Allopurinol | Allopurinol | 49 | 14 |
| Potassium Chloride | Potassium Chloride | 45 | 12 |
| Tramadol Hcl | Tramadol Hcl | 42 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Prednisone | Prednisone | 35 | 32 |
| Spironolactone | Spironolactone | 35 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | 11 |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 23 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | 11 |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 19 |
| Finasteride | Finasteride | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Simvastatin | Simvastatin | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Fluvastatin Sodium | Fluvastatin Sodium | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | 11 |
| Cephalexin | Cephalexin | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $335.30 · 4 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, DUPIXENT, FASENRA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error